You are here

Retours TransAtlantiques: FerInject – lessons from the European experience

By Yves Beguin, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

16 - Yves Beguin ANG

The topic of Yves Beguin’s presentation is how to treat anemia in cancer patients, particularly using intravenous iron supplementation (FerInject) instead of oral iron. He explains the differences between absolute iron deficiency in which no iron stores are present and functional iron deficiency, i.e. iron deficiency in erythroid bone marrow, which is due to iron sequestration in macrophages or increased iron requirements, for example caused by EPO therapy. Intravenous iron improves transferrin saturation and it has been shown that hematopoietic response is considerably higher with intravenous iron compared to EPO alone. With the addition of intravenous iron to EPO, EPO use can be reduced which leads to cost savings. Yves Beguin also presents data of several trials on the use of intravenous iron alone.

Yves Beguin, CHU de Liège, Belgium

Search this site

Featured videos

Free access to ebooks on cachexia and CINV


Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

Cancer cachexia: mechanisms and progress in treatment


Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo